Pleiotropic effects of trimetazidine

Aim. To investigate potential pleiotropic effects of trimetazidine (PreductalMB) in patients with stable effort angina. 

Material and methods. This randomised controlled clinical study included 95 patients with Functional Class I–III stable effort angina and Stage 2–3 arterial hypertension. Clinical effectiveness of pharmacological therapy was assessed by expert-evaluated subjective and objective criteria, with the calculation of the treatment effectiveness index (%) (Patent No. 58859 A [8],Ukraine). 

Results. The complex pharmacological therapy of coronary heart disease (CHD) was twice as effective after the addition of trimetazidine, due to increased antianginal action and exercise capacity. Trimetazidine also reduced energy deficiency and tissue hypoxia in myocardial ischemia. Pleiotropic effects of trimetazidine (antiatherosclerotic, anti-inflammatory, and stress-limiting) could justify the extended indications for this medication. 

Conclusion. In a randomised clinical trial including patients with stable effort angina, the effectiveness of complex pharmacotherapy was doubled by additional administration of trimetazidine (Preductal MB 35 mg twice per day for 6 weeks), due to increased antianginal effects and exercise capacity.

1. Fesenko E. V., Proschaev K. I., Poljakov V. I. Pleiotropic effects of statin’s treatment and its role in overcoming of polymorbidity’s problem // Modern problems of education and science. 2012; 2. Russian (Фесенко Э. В., Прощаев К. И., Поляков В. И. Плейотропные эффекты статинотерапии и их роль в преодолении проблемы полиморбидности.

2. Современные проблемы науки и образования. 2012; 2).

3. Sturov N. V. Pleiotropic effects of ACEI. Difficult patient. 2006; 7: 18–21. Russian (Стуров Н. В. Плейотропные эффекты ИАПФ. Трудный пациент. 2006; 7:18–21).

4. Diagnostics and treatment of stable angina. Russian recommendations (second edition). Designed by Committee of experts of Russian scientific society of cardiologists. Cardiovascular therapy and prevention 2008; 7 (8):1–40. Suppl. 4. Russian (Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Разработаны Комитетом экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7 (8):1–40. Приложение 4).

5. Astashkin E. I., Glezer M. G. Metabolic cytoprotectors and mechanism of theirs action. Energetic metabolism of heart. Issue 1. Moscow, 2009. Russian (Асташкин Е. И., Глезер М. Г. Метаболические цитопротекторы и механизмы их действия. Энергетический обмен сердца. Выпуск 1. Москва, 2009. 13с).

6. Astashkin E. I. Correction of energetic metabolism in myocardium – new direction in treatment of cardiovascular diseases. Heart and metabolism. 2008; 21:1–3. Russian (Асташкин Е. И. Коррекция энергетического обмена в миокарде – новое направление в лечении сердечно-сосудистых заболеваний. Сердце и метаболизм. 2008; 21:1–3).

7. Alexandrov A. A. Clinical horizons of cardioprotection: “calcium track” of trimetazidine./CONSILIUM–MEDICUM. 2005; 7, 9: 757–63. Russian (Александров А. А. Клинические горизонты кардиопротекции: “кальциевый след” триметазидина. CONSILIUM–MEDICUM. 2005; 7, 9;757–63).

8. Guarnieri C., Muscary C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hyperthrofied myocardium. Pharmacology. 1993; 46:324–31.

9. Райгородский Д. Я. Практическая психодиагностика. Методики и тесты. – Самара: Издательский дом “Бахрах-М”, 2000. 672с. (RaygorodskiyD.Ya. Practical psychodiagnostics. Methodics and tests. – Samara: Publishing house Bachrach-M, 2000. 672.)

10. Markov Kh. M. Nitric oxide and atherosclerosis. Pharmacotherapy of atherosclerosis and nitric oxide. Cardiology. 2011; 3:86–94. Russian (Марков Х. М. Оксид азота и атеросклероз. Фармакотерапия атеросклероза и оксид азота. Кардиология 2011;3:86–94).

11. Napoli P. Di., Taccardi A. A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart. 2005; 91:161–5.